Cardiovascular Mortality Reduction With Empagliflozin in Patients With Type 2 Diabetes and Cardiovascular Disease

Journal of the American College of Cardiology

Volumn 71, Issue 3, 2018, Pages 364-367

  Fitchett, David ^a   Inzucchi, Silvio E ^a   Lachin, John M ^a   Wanner, Christoph ^a   van de Borne, Philippe ^a   Mattheus, Michaela ^a   Johansen, Odd Erik ^a   Woerle, Hans J ^a   Broedl, Uli C ^a   George, Jyothis T ^a   Zinman, Bernard ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EMPAGLIFLOZIN; BENZHYDRYL DERIVATIVE; GLUCOSIDE;

ALL CAUSE MORTALITY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; HAZARD RATIO; HUMAN; LETTER; MORTALITY RISK; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; RISK REDUCTION; CLINICAL TRIAL; MORTALITY; TRENDS;

BENZHYDRYL COMPOUNDS; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; GLUCOSIDES; HUMANS; MORTALITY; SODIUM-GLUCOSE TRANSPORTER 2 INHIBITORS;

EID: 85044671003     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2017.11.022     Document Type: Letter

References (5)

1. Di Angelantonio, E., Kaptoge, S., Wormser, D., et al., for the Emerging Risk Factors Collaboration. Association of cardiometabolic multimorbidity with mortality. JAMA 314 (2015), 52–60.
2. Zinman, B., Wanner, C., Lachin, J.M., et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med 373 (2015), 2117–2128.
3. U.S. Department of Health and Human Services Food and Drug Administration. Multiple endpoints in clinical trials guidance for industry. 2017. Available at: www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm536750.pdf. Accessed November 22, 2017.
4. Kaul, S., Is the mortality benefit with empagliflozin in type 2 diabetes mellitus too good to be true?. Circulation 134 (2016), 94–96.
5. Sattar, N., McLaren, J., Kristensen, S.L., Preiss, D., McMurray, J.J., SGLT2 inhibition and cardiovascular events: why did EMPA-REG OUTCOMES surprise and what were the likely mechanisms?. Diabetologia 59 (2016), 1333–1339.